Featured Content
The Center for Life Science Ventures was founded in 2008 as a startup incubator to help develop young Cornell life science companies. The Center is funded through the Office of the Vice President for Research and Innovation, the Institute of Biotechnology and NYSTAR.
The Center’s program focuses on accelerating research and development of its client’s companies’ technology and products, validating its client companies’ business plans, and strengthening their management teams. The Center’s goal is to facilitate the forward progress of client companies to the point where each will merit significant outside investment, and achieve self-sufficiency. In doing so, the Center for Life Science Ventures contributes to the University’s mission as New York State’s Morrill Land Grant institution to support local, regional, and state-wide Life Sciences jobs/economic development.
News
Funding fuels trials for CareTech Human’s health technology
1747094400
A Cornell-based startup is advancing a solution that could improve care for the millions of people suffering from urological conditions in the U.S. CareTech Human, a member of Cornell’s Center for Life Science Ventures, has …
Cornell incubators propel startups toward real-world impact
1745971200
By Bridget Hagen, Cornell Research & Innovation Cornell’s incubator Class of 2025, composed of startups Llume, Meiogenix and TETmedical, is advancing innovations in human performance monitoring, non-GMO plant breeding and neurological critical care. From left, …
New biodegradable graft could help cardiovascular patients
1738195200
By Susan Kelley, Cornell Chronicle January 21, 2025 Cornell engineers are aiming to create a big leap in vascular grafts, used to combat cardiovascular disease, the leading cause of death worldwide. The biodegradable graft looks like …
Center Graduate Kanvas Biosciences Secures Additional $12.5M to Advance Its Novel, Microbiome-Based Immuno-oncology Drug Candidates to IND Filing
1720483200
https://www.prnewswire.com/news-releases/kanvas-biosciences-secures-additional-12-5m-to-advance-its-novel-microbiome-based-immuno-oncology-drug-candidates-to-ind-filing-302184016.html With $29.5 million in total funding, the company has developed the world’s leading spatial biology platform, designed for breakthroughs in drug development, clinical diagnostics, agriculture, and food safety. This proprietary mapping technology will first be used …